Related Experiment Video
Updated: Jun 30, 2026

Teratoma Generation in the Testis Capsule
Published on: November 7, 2011
Testicular germ-cell cancer
Alan Horwich1, Janet Shipley, Robert Huddart
1Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey SM2 5PT, UK. alan.horwich@icr.ac.uk
Abstract:
Testicular germ-cell tumours (TGCTs) represent the model of a curable malignancy; sensitive tumour markers, accurate prognostic classification, logical series of management trials, and high cure rates in both seminomas and non-seminomas have enabled a framework of effective cancer therapy. Understanding the molecular biology of TGCT could help improve treatment of other cancers. The typical presentation in young adults means that issues of long-term toxicity become especially important in judging appropriate management. A focus of recent developments has been to tailor aggressiveness of treatment to the severity of the prognosis. Recent changes affect the most common subtypes and include the reduction of chemotherapy for patients who have metastastic non-seminomas and a good prognosis, and alternatives to adjuvant radiotherapy in stage I seminomas. We summarise advances in the understanding and management of TGCT during the past decade.
Insights
Testicular germ-cell tumors (TGCTs) are highly curable cancers. Advances focus on tailoring treatment to prognosis, reducing chemotherapy for good-prognosis metastatic non-seminomas and offering alternatives to radiotherapy for stage I seminomas.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Testicular germ-cell tumors (TGCTs) are a model for curable malignancies.
- Understanding TGCT molecular biology may inform other cancer treatments.
- Management must consider long-term toxicity in young adults.
Purpose of the Study:
- To summarize recent advances in TGCT understanding and management over the past decade.
- To highlight the tailoring of treatment aggressiveness based on prognostic severity.
- To review changes in managing common TGCT subtypes.
Main Methods:
- Review of recent developments in testicular germ-cell tumor management.
- Analysis of changes in chemotherapy protocols for metastatic non-seminomas.
- Evaluation of alternatives to adjuvant radiotherapy for stage I seminomas.
Main Results:
- Reduced chemotherapy is now recommended for metastatic non-seminomas with a good prognosis.
- Alternatives to adjuvant radiotherapy are available for stage I seminomas.
- Treatment strategies are increasingly tailored to individual patient prognosis.
Conclusions:
- Testicular germ-cell tumors represent a highly curable malignancy with evolving treatment paradigms.
- Recent advances focus on reducing treatment intensity and toxicity.
- Personalized management based on prognosis is improving TGCT outcomes.
Related Concept Videos
Cancer
Cancers Originate from Somatic Mutations in a Single Cell
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancers Originate from Somatic Mutations in a Single Cell
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

